SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Onyx Pharmaceuticals, Inc. Completes Enrollment in FOCUS Phase 3 Carfilzomib Trial in Patients With Relapsed and Refractory Multiple Myeloma